Strategy for improving retransplantation in the CyA era.
Dickerman
R
R
Department of Transplantation, Methodist Hospitals of Dallas, Texas 75265-5999.
Langley
J
J
Brinker
K
K
Trevino
G
G
Melton
L
L
Vergne-Marini
P
P
Wilson
P K
PK
D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006085:Graft Survival; D006680:HLA Antigens / Q000032:analysis; D006650:Histocompatibility Testing; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D016853:Muromonab-CD3 / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D012189:Retrospective Studies; D013997:Time Factors
D000961:Antilymphocyte Serum; D006680:HLA Antigens; D016853:Muromonab-CD3; D016572:Cyclosporine; D001379:Azathioprine; D011241:Prednisone